ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1031

Access to Advanced Therapies in Axial Spondyloarthritis in Latin America, Data from the PANLAR-ESPALDA Registry

Rodrigo Garcia Salinas1, Fernando Andres Sommerfleck2, Diego Vila3, Daniel Palleiro4, Daniel Fernández-Ávila5, Julio César Casasola Vargas6, Maria Amada Barcia7, Dora Liliana Candia Zuniga8, Nicolas Martin Marin Zucaro9, María Lorena Brance10 and Wilson Bautista-Molano11, 1Hospital Italiano La Plata, La Plata, Argentina, 2Sanatorio Julio Mendez, Buenos Aires, Argentina, 3Hospital Virgen del Carmen, Campana, Buenos Aires, Argentina, 4Instituto Nacional de Reumatologia, Montevideo, Uruguay, 55Hospital San Ignacio, Colombia, BOGOTA, Colombia, 6Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, 77Hospital General Portoviejo del Instituto Ecuatoriano de Seguridad Social (IESS), Guayaquil, Ecuador, 88Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, Mexico City, Mexico, 9Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 10School of Medicine, Rosario National University, Argentina, Rosario, Argentina, 11University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia

Meeting: ACR Convergence 2024

Keywords: , , ,

Session Information

Date: Sunday, November 17, 2024

Title: Healthcare Disparities in Rheumatology Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Access to advanced treatments in LATAM poses challenges due to various socioeconomic factors. The PANLAR-ESPALDA registry was established with the objective of gathering data specific to our region. The primary aim of this study is to described the frequency of advanced therapy in axSpA and analyze the characteristics of the patients receiving such treatments.

Methods: We included consecutive patients aged ≥18 years with axSpA (ASAS 2009) from medical centers in Argentina, Uruguay, Chile, Venezuela, Mexico, Colombia, and Ecuador. Recorded data encompassed demographic information, age at symptom onset, disease duration, disease-related symptoms, and comorbidities. Clinical and therapeutic aspects of the disease were documented at baseline, and specific questionnaires ASDAS/BASDAI/BASFI were administered. Additionally, we recorded erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) in mg/dl, HLA-B27, X-rays, and, MRI of the sacroiliacs.

Results: A total of 200 patients were recruited, with a mean age of 46 years, and 54.5% were male (Table 1) Of the total, 49% (95% CI: 42-56) were on advanced therapy (following NSAID failure) at the baseline visit: TNFi: 80%, L17i: 15%, and Jaki: 5%. Ten percent of patients were in their second line of treatment. The characteristics of patients under advanced treatment (only the significant ones and disease activity) are detailed in table 1. More than 50% of patients without advanced therapies still presented disease activity (BASDAI > 4). In multivariate analysis, the characteristics independently associated with the use of advanced therapy were smoking (OR 2.8, 95% CI: 0.2-6.5) and HLA-B27 positivity (OR 4, 95% CI: 1.7-9).

Conclusion: In our region, the frequency of advanced therapy use in axSpA is 50%. Patients under these treatments tend to exhibit a more “typical” disease profile, including radiographic evidence, HLA-B27 and peripheral manifestations. Even with disease activity, a high subset of patients remains without these advanced therapies.

Supporting image 1

Table 1

Supporting image 2

Figure 1

Supporting image 3

Table 2

Disclosures: R. Garcia Salinas: AbbVie/Abbott, 2, 6, Amgen, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, Janssen, 2, 6, Novartis, 6, Pfizer, 6, Roche, 6; F. Sommerfleck: AbbVie/Abbott, 2, 6, Eli Lilly, 6, Janssen, 2, 6, Novartis, 2, 6; D. Vila: None; D. Palleiro: None; D. Fernández-Ávila: None; J. Casasola Vargas: None; M. Barcia: None; D. Candia Zuniga: None; N. Marin Zucaro: None; M. Brance: None; W. Bautista-Molano: Janssen, 5.

To cite this abstract in AMA style:

Garcia Salinas R, Sommerfleck F, Vila D, Palleiro D, Fernández-Ávila D, Casasola Vargas J, Barcia M, Candia Zuniga D, Marin Zucaro N, Brance M, Bautista-Molano W. Access to Advanced Therapies in Axial Spondyloarthritis in Latin America, Data from the PANLAR-ESPALDA Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/access-to-advanced-therapies-in-axial-spondyloarthritis-in-latin-america-data-from-the-panlar-espalda-registry/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/access-to-advanced-therapies-in-axial-spondyloarthritis-in-latin-america-data-from-the-panlar-espalda-registry/